Molecular Aberrations Associated With Seizure Control In Diffuse Astrocytic And Oligodendroglial Tumors by 鈴木 比女
 
 






Molecular Aberrations Associated With Seizure Control In 
Diffuse Astrocytic And Oligodendroglial Tumors 
(低悪性度脳腫瘍における症候性てんかんの病理学的検討) 
Author(s) 
著  者 鈴木, 比女 
Degree number 
学位記番号 




















Molecular Aberrations Associated With Seizure Control In Diffuse Astrocytic And 
Oligodendroglial Tumors 
 
Hime Suzuki 1, Nobuhiro Mikuni 1, Shintaro Sugita 2, Tomoyuki Aoyama 2, Rintaro 
Yokoyama, 1 Yuto Suzuki 1, Rei Enatsu 1, Yukinori Akiyama 1, Takeshi Mikami 1, 
Masahiko Wanibuchi 1, Tadashi Hasegawa 2 
 
1Department of Neurosurgery, Sapporo Medical University 
2Department of Surgical Pathology, Sapporo Medical University 
 
Correspondence and reprint requests should be addressed to: Nobuhiro Mikuni 
Mailing address: South 1 West 16, Chuo-ku, Sapporo 060-8543, Japan 
Department of Neurosurgery, Sapporo Medical University 
Phone: +81-11-611-2111          Fax: +81-11-614-1662 
Email: mikunin@sapmed.ac.jp 
 
Key words: glioma; oligodendroglioma; diffuse astrocytoma; epilepsy 
 






Background: Diffuse astrocytic and oligodendroglial tumors are frequently associated 
with symptomatic epilepsy, and predictive seizure control is important for the 
improvement of patient quality of life. To elucidate the factors related to drug resistance 
of brain tumor-associated epilepsy from a pathological perspective. 
Method: From January 2012 to October 2017, 36 patients diagnosed with diffuse 
astrocytic or oligodendroglial tumors were included. Assessment for seizure control was 
performed according to the Engel classification of seizures. Patient clinical, radiological, 
and pathological data were stratified based on the following 16 variables: age, sex, 
location of tumor, existence of the preoperative seizure, extent of resection, 
administration of temozolomide, radiation therapy, recurrence, Karnofsky performance 
scale, IDH-1, 1p/19q co-deletion, Olig2, PDGFR-α, p53, ATRX, and Ki67. These factors 
were compared between the well-controlled group and drug-resistant seizure group. 
Results: Twenty-seven patients experienced seizures; of these, 14 cases were well-
controlled, and 13 cases were drug-resistant. Neither clinical nor radiological 
characteristics were significantly different between these two groups, though p53 
immunodetection levels were significantly higher, and the frequency of 1p/19q co-
deletion was significantly lower in the group with drug-resistant seizures than in the well-
controlled group. In the multivariate analysis, only one item was selected according to 
stepwise methods, and a significant difference was observed for p53 (OR, 21.600; 95% 
CI, 2.135–218.579; p = 0.009). 
Conclusion: Upregulation of p53 may be a molecular mechanism underlying drug 






Diffuse astrocytoma and oligodendroglioma are classified as low grade gliomas (LGG) 
in accordance with the 2016 revision of the World Health Organization (WHO) criteria 
for brain tumors. Diffuse astrocytoma and oligodendroglioma account for around 70% of 
LGG 1. The prevalence of seizures is 60-88% in patients with LGG, whereas the five 
years survival rate of these patients is around 70-90% 2-4. Therefore, it is important to 
achieve better seizure control to improve the patients’ quality of life5, 6. It has been 
reported that approximately 30% of the cases are uncontrolled seizures, regardless of 
appropriate treatment with antiepileptic drugs for epilepsy associated with LGG 7. Tumors 
causing drug-resistant seizures for more than two years are a cumbersome problem, and 
are defined as “long-term epilepsy-associated tumors” 8.  
Recently, the risk factors for brain tumor-associated epilepsy were evaluated in 
LGG cases, especially seizure control 9. The efficacy of tumor treatment is important for 
seizure control 4, 10-13, as maximal resection improves seizure control. Moreover, in 80% 
of patients with temporal lesion of Engel class I, seizure control was achieved with 
maximal resection 6, 14. Radiotherapy of WHO grade II patients resulted in a reduction 
of seizure frequency by 50% in 76% of the patients at 3 months after therapy, while there 
were no apparent changes in tumor responses on magnetic resonance imaging (MRI) 15, 
16. Nevertheless, seizure control is achieved upon chemotherapy regardless of the 
regimen 10. Temozolomide (TMZ), which is generally used in LGG and malignant 
gliomas, resulted in 50% reduction in seizure frequency in 48% of patients 17, 18.  
From a histopathological point of view, oligodendrogliomas are more often 
associated with the prevalence of seizures than are astrocytomas. It has been reported 




expression levels of Ki67 are associated with seizure occurrence 7, 23. Although these 
studies were focused on seizure occurrence, little is known about the factors associated 
with the degree of drug-resistant seizures. In this report, we analyzed the clinical and 
pathological factors associated with drug-resistance in brain tumor-associated epilepsy 
in patients with astrocytic and oligodendroglial tumors. 
 
Materials and Methods 
Description of patient population 
We declare that this study has been approved by institutional ethics committee, and have 
been performed in accordance with the ethical standards of the 1964 Declaration of 
Helsinki and its later amendments. The study protocol was approved by the Ethics 
Committee of Sapporo Medical University Hospital (No. 292-242). All patients provided 
informed consent before participating. From January 2012 to October 2017, 48 
consecutive patients were diagnosed with diffuse astrocytic or oligodendroglial tumors 
(WHO grade II) either by analysis of specimens collected after brain tumor resection or 
through biopsy at our institute. Pathological diagnosis was based on the WHO guidelines, 
as revised in 2016 24. A minimum postoperative follow-up period of 12 months was 
required. Consequently, patients diagnosed with diffuse astrocytoma with IDH-1 
mutation, oligodendroglioma with IDH-1 mutation and 1p/19q co-deletion, diffuse 
astrocytoma with wild-type IDH-1, and oligodendroglioma NOS (not-otherwise-
specified) were included. 
We evaluated each case for seizure control at least 12 months after its recurrence. 
The patients were classified into two groups based on the extent of seizure control. 




seizures 25. Cases of Engel class I and II were classified as well-controlled, and cases of 
class III and IV were classified as drug-resistant in accordance with the study of Kwan et 
al.26. 
MRI examination was performed using a 3.0-T system (Signa Excite, version 11, 
GE Medical Systems) preoperatively, at 1 day and 1 month after operation. Subsequently, 
MRI was performed every 6 months. T1-weighted, gadolinium enhanced T1-weighted, 
T2-weighted, and fluid-attenuated inversion recovery sequences were used for evaluation.  
 Patient clinical and radiological data were stratified based on the following 9 
variables: (1) age; (2) sex; (3) tumor location (frontal, temporal, other); (4) presence of 
the preoperative seizure; (5) extent of tumor resection (≥ 95%; gross total resection and 
subtotal resection as a border, < 95%; partial resection and biopsy); (6) TMZ 
administration; (7) radiation therapy; (8) decrease of tumor volume of < 50% or ≥ 50% 
after treatment with operation, radiation, and chemotherapy; (9) recurrence; (10) 
neurological symptoms; (11) Karnofsky performance scale (KPS). The clinical and 
radiological factors were compared between the well-controlled group and drug-resistant 
seizure group. 
 
Detection of 1p/19q co-deletion by fluorescence in situ hybridization (FISH) 
We performed FISH using Vysis LSI 1p36/LSI 1q25 and LSI 19q13/19p13 Dual-Color 
Probe (Abbott, Abbott Park, IL, USA) for 1p36 and 19q13 deletion. Each of the probes 
was labeled with red and green fluorescence in target and control loci, respectively. FISH 
was conducted on formalin-fixed, paraffin-embedded specimens sectioned into 4-μm 
slices on glass slides, as previously described 27-29. We counted 50 tumor nuclei and 




homozygous deletions, heterozygous deletions, and monosomy patterns. A homozygous 
deletion involved a complete deletion of the target locus in both alleles and exhibited only 
control green signal. A heterozygous deletion corresponded to the deletion of either of 
the target loci in one allele; the red signals for the target loci were detected in less nuclei 
than the green signals for control loci. Tumor cells with monosomy had one allele, and 
exhibited a pair of red and green signals. Monosomy was also considered as one of the 
patterns of heterozygous deletion. The results of FISH were confirmed by T.A., S.S., and 
T.H. 
 
Pathological assessment by immunohistochemistry 
We performed immunohistochemistry on formalin-fixed, paraffin-embedded specimens 
cut into 3 μm-thick sections. We used antibodies against the following antigens: IDH-1 
(H09, Dianova, Hamburg, Germany), ATRX (ab97508, Abcam, Cambridge, MA, USA), 
p53 (DO-7, BioGenex, Fremont, CA, USA), Olig2 (polyclonal, IBL, Gunma, Japan), 
platelet-derived growth factor receptor alpha (PDGFRα, 5241, Cell Signaling Technology, 
Danvers, MA, USA), and Ki67 (Ki67, Agilent Technologies, Santa Clara, CA, USA).  
 Figure 1 illustrates the scoring for each immunostaining. Scoring for Olig2 and 
PDGFR-α was done per specimen on a 4-point scale, from 0 to 3, at ×200 magnification, 
defined as follows: 0 corresponded to no or rare staining and 1 corresponded to <10%, 2 
corresponded to 10%-49%, and 3 corresponded to ≥50% of positively stained cells. 
Scores for p53 and ATRX were analyzed per specimen at ×200 magnification, using a 
scale of 0–1 (0 corresponded to low expression [<10%], and 1 corresponded to high 
expression [≥10%]). Scoring for Ki67 was done on a 2-point scale, from 0 to 1 (0 




estimated by 2 neuro-oncologists (H.S. and T.M.) and 1 pathologist (S.S.). The 
pathological factors were compared between the group with seizures and the seizure-free 
group, and between the well-controlled and drug-resistant seizure groups. 
 
Statistical analysis 
Data are expressed as median (interquartile range). Mann-Whitney U-test and Fisher’s 
exact probability tests were used for the comparison between the groups of patients with 
well-controlled seizures and patients with drug-resistant seizures. For tests that resulted 
in p < 0.05, simple logistic regression was used in the univariate analyses. Odds ratios 
(ORs) were obtained through these models with 95% confidence intervals (Cis). Each 
item was then selected according to stepwise methods (model selection criterion, 0.10), 
and a multivariate analysis of all potential factors associated with drug-resistant seizure 
was performed. Kaplan-Meier estimates were used to assess the drug-resistance of 
seizures in patients with epilepsy. Endpoint was set at the day of recurrence of seizure. 
All statistical analyses were conducted using the SPSS software package (version 24.0, 




Three patients with poor quality of specimens and 9 patients with insufficient specimens 
for histopathological analysis were excluded from 48 patients. A total of 36 patients (19 
men and 17 women) were enrolled and retrospectively analyzed with regards to the 
presence of drug-resistant seizures. In terms of pathological diagnosis, 26 cases carried 




cases carried the 1p/19q co-deletion and 13 cases did not. Pathological diagnosis 
according to the 2016 WHO guidelines was diffuse astrocytoma with IDH-1 mutation in 
14 cases, diffuse astrocytoma with wild-type IDH in 8 cases, oligodendroglioma with 
IDH-1 mutation and 1p/19q co-deletion in 13 cases, and oligodendroglioma with NOS in 
1 case. The median patient age at the time of surgery was 35.5 years (interquartile range, 
27.3-51.5; range, 4-82 years). The median follow-up period was 31.7 months 
(interquartile range, 24.7–65.9; range, 12.2–213.1 months). Mortality was observed at 
1841 days, 2050 days, and 745 days after diagnosis in 1 case of diffuse astrocytoma with 
IDH-1 mutation and 2 cases of diffuse astrocytoma with wild-type IDH-1, respectively. 
During the follow-up period, 27 out of 36 patients had seizures. Of these, 21 
patients experienced seizures from disease onset, while 6 patients experienced seizures 
postoperatively. Mean duration from initial epileptic seizure to surgical intervention was 
120 days in 21 cases; among these cases, focal to bilateral tonic-clonic seizures were 
presented in 12 patients, focal seizures with awareness in 5 patients, and focal seizures 
without awareness in 4 patients. Inducible seizures occurring only during the 
perioperative period were excluded. Seizures were classified based on the operational 
classification of seizure types by the International League Against Epilepsy 30, and the 
results were as follows: 14 patients presented with focal to bilateral tonic-clonic seizures, 
9 with focal seizures with awareness, and 4 with focal seizures without awareness.  
Levetiracetam was used as the first-choice anticonvulsant in 22 cases; it was 
frequently used after it became available in our hospital. Other anticonvulsants included 
carbamazepine (6), lacosamide (3), phenobarbital (1), and sodium valproate (1). When 
seizures recurred, we weighted the drug or administered a different drug. The decision 




because of drug-resistance: lacosamide (3), zonisamide (3), carbamazepine (2), 
lamotrigine (2), perampanel (2), and levetiracetam (1). There were 8 cases receiving two 
kinds of anticonvulsants, 3 cases receiving three kinds of anticonvulsants, and 2 cases 
receiving four kinds of anticonvulsants. An additional anticonvulsant was not 
administered in any of these cases because of side effects of the previously administered 
anticonvulsant. TMZ Chemotherapy was performed on 25 patients with administration of 
75 mg/m2 for 42 days (10) and 150 mg/m2 for 5 days (15). Radiation therapy was 
performed for 14 patients: 60 Gy/30 fr (8), 54 Gy/30 fy (4), 54 Gy/28 fr (1), and 46 Gy/23 
fr (1). 
 
The control of seizures in low grade glioma 
Table 1 shows clinical and radiographical characteristics in the well-controlled group and 
the drug-resistant seizure group. The well-controlled group included 14 cases (51.9%) 
and the drug-resistant group included 13 cases (48.1%); in the well-controlled group, 
multiple anti-convulsant drugs were administered in 1 patient, and in the drug-resistant 
group, multiple drugs were administered in 12 patients. The median age was 43.5 years 
(range, 33.8-58.3) in the well-controlled group, and 32.0 years (range, 21.0-42.5) in the 
drug-resistant seizure group indicating that the younger patients exhibited unfavorable 
control of seizures (p = 0.038); neurological symptoms were observed in 1 case in the 
well-controlled group, and in 6 cases in the drug-resistant group (p = 0.021). There were 
no significant differences in sex, location of tumor, existence of the preoperative seizure, 
extent of tumor removal, prescription of TMZ, irradiation therapy, Tumor volume after 
treatment, and tumor recurrence between the two groups (p = 0.180, 0.486, 0.385, 1.000, 




the well-controlled group, and 90, (range, 40-100), in the drug-resistant seizure group (p 
= 0.375). Therefore, the clinical characteristics of age and neurological symptoms were 
significantly associated with seizure control. 
From a pathological point of view, 5 cases (35.7%) in the well-controlled group 
and 12 cases (92.3%) in the drug-resistant seizure group were positive for p53 
immunostaining and this difference was statistically significant (p = 0.004). Thus, the 
patients with p53-immunopositive tumors exhibited unfavorable seizure control. On the 
other hand, 8 cases (57.1%) in well-controlled group and 2 cases (15.4%) in the drug-
resistant seizure group had the 1p/19q co-deletion and this difference was statistically 
significant (p = 0.046), indicating that the patients without 1p/19q co-deletion mostly had 
drug-resistant seizures. There was no significant difference in immunodetection of IDH-
1 between the well-controlled and drug-resistant seizure groups (p = 0.209). Moreover, 
immunostaining scores for Olig2, PDGFRα, and ATRX were not significantly different 
between the well-controlled and drug-resistant groups (p = 0.072, 0.863, 0.816, 
respectively). Additionally, high Ki67 expression (> 5%) was detected in 6 cases (42.9%) 
in the well-controlled group and 6 cases (46.2%) in the drug-resistant group (p = 0.863). 
Consequently, the presence of p53 and 1p/19q co-deletion were identified to have a 
statistically significant association with seizure control. 
The univariate analysis associated with drug-resistant seizure in patients with 
diffuse astrocytic and oligodendroglial tumors are presented in Table 2. In the univariate 
analysis, the prevalence of drug resistant seizure was associated with neurological 
symptoms (OR, 11.143; 95% CI, 1.108-112.012; p = 0.041), 1p/19q co-deletion (OR, 
0.136; 95% CI, 0.022–0.860; p = 0.034) and p53 (OR, 21.600; 95% CI, 2.135–218.579; 




methods, and a significant difference was noted in the p53 (OR, 21.600; 95% CI, 2.135–
218.579; p = 0.009). 
 Twenty-seven patients with seizures were included in Kaplan-Meier estimation 
(Figure 2. a-c). The endpoint for the assessment of drug-resistance was defined as the day 
of recurrence seizure. The mean periods between seizure recurrence were 63.0 months 
(95% CI, 41.3-84.7) in the patients with the 1p/19q co-deletion versus 19.5 months (95% 
CI, 10.3-28.7) in the patients without 1p/19q co-deletion (p = 0.016). The mean periods 
for seizure recurrence were 16.1 months (95% CI, 8.7-23.5) in the patients with p53 
upregulation versus 67.8 months (95% CI, 46.6-89.0) in the patients without p53 
upregulation (p = 0.001). Moreover, the mean periods controlled by a single 
anticonvulsant were 50.5 months (95% CI, 27.7-73.3) in the patients with ATRX 
immunodetection versus 20.8 months (95% CI, 13.0-28.7) in the patients without ATRX 
staining (p = 0.181). 
 
Discussion 
The role of p53 in the control of seizures in patients with LGG 
The results of our study indicated that the control of seizures in diffuse astrocytoma and 
oligodendroglioma is associated with p53 immunopositivity. This is the first study 
reporting that p53 is related to the drug-resistance of seizures. p53 is a major tumor 
suppressor gene that is located on human chromosome 17p13 and plays an important role 
in cellular homeostasis by DNA repair, control of apoptosis, and regulation of the cell 
cycle 32. Many types of cancer present abnormalities in p53 such as loss and mutation. In 
gliomas, immunodetection of p53 upregulation is indicative of the presence of p53 




astrocytoma and oligodendroglioma and seizure control has not been investigated. In 
preclinical studies on rats, normal p53 levels had an inhibitory effect on epilepsy. Engel 
et al. reported that lacking normal p53 results in prolongation of electrographic seizures 
and aggravation of the epileptic phenotype 36. p53 is associated with neuronal death. 
Neuronal impairment induced by excessive neuronal excitotoxity and prolonged seizures 
results in upregulation of p53, induction of DNA repair, and apoptosis. Indeed, in human 
temporal epilepsy and animal temporal epilepsy models, the levels of normal p53 were 
elevated in the hippocampus, and the absence of p53 was related to worse seizure 
outcomes because of seizure-induced neuronal death 37-39. Duan et al. reported that 
epilepsy nerve cell apoptosis is regulated by the genes such as p53, Bcl, and Bax, and 
they exhibit a neuroprotective effect.40 Therefore, p53 abnormalities might facilitate 
further intractability of seizures when epileptogenesis is established. 
 Our results demonstrated that the good control of seizures was also associated 
with 1p/19q co-deletion. This result is consistent with a previous report by You G et al 23. 
With regard to the histopathology of the tumor, reciprocal characteristics between p53 
mutation and 1p/19q co-deletion seem to exist, which can be adapted for the design of 
seizure control treatments. Only p53 was selected in the multivariate analysis, which 
revealed that p53 is a strong factor for seizure control. In addition, Olig2, a marker of 
mature oligodendrocytes, and PDGFRα, a marker of immature oligodendrocytes, were 
not significantly associated with seizure control. Therefore, the outcome on seizure 
control could not be explained by the pathological identity of oligodendrogliomas. 
Furthermore, it is reported that 80% of ATRX immunopositivity was detected in p53-
positive diffuse astrocytoma and oligodendroglioma 41 and, in our study ATRX 




Consequently, our results suggest that the drug-resistance of seizures is caused by p53 
signaling in diffuse astrocytoma and oligodendroglioma, but via a pathway different than 
p53-ATRX. 
 With regard to clinical characteristics, neurological symptoms such as 
hemiparesis and aphasia are related to the anatomical and functional location of the 
tumors and risk factors of epileptic seizure 42, 43. Moreover, the recurrence and malignant 
progression were related to epileptic seizure status and there were no significant 
differences in existence of preoperative seizure. It was considered that these patients with 
preoperative seizures were treated surgically before acquisition of drug-resistance 42. 
However, in the multivariate analysis performed in our study, we excluded these factors 
and only included p53.  
 
Limitation 
This study had several limitations. First, pathological factors presented in this study were 
estimated by immunostaining procedures. Since the WHO brain tumor classification was 
revised in 2016, a molecular evaluation and assessment would be necessary for brain 
tumor diagnosis. The second problem is the validity of the evaluation and assessment for 
seizures. The Engel classification, which was used for the assessment of seizure control, 
bears some discrepancies between the original use for idiopathic epilepsy and the 
adaptation for brain tumor-associated epilepsy 7, 16, 44, 45. Moreover, the follow-up period 
was shorter than that used in idiopathic epilepsy. This is the most important discrepancy 
between the conventional approach for brain tumor-related epilepsy and the original 
approach for idiopathic epilepsy. Finally, this study involved a relatively small number of 




was performed using a univariate nonparametric test for all comparisons. In addition, the 
influence on epileptic seizure by each treatment result was not assessed. Studies with 
larger sample sizes are needed in the future for the confirmation of our observations. 
 
Conclusion 
In diffuse astrocytoma and oligodendroglioma, the upregulation of p53 was associated 
with drug-resistance. In seizure control, there was a reciprocal association between p53 
mutation and 1p/19q co-deletion as evidenced by the pathological characteristics of the 
tumors. In cases of diffuse astrocytoma and oligodendroglioma, long-life prognosis and 
disease-free survival are anticipated. Therefore, the assessment and prognosis of brain 
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Figure 1. Microscopic images of tumor specimens stained by immunohistochemistry with 
different scores. 
(a) Scoring for Olig2 was defined follows: 0 corresponds to no or rare staining, 1 
corresponds to <10% of positively stained cells, 2 to 10%-49%, and 3 to ≥50% of 
positively stained cells, at ×200 magnification. (b) Scoring for Ki67 was defined follows: 
0 corresponds to <5%, and 1 to ≥5% of positively stained cells, at ×200 magnification. 
(c) Scoring for p53 was defined as follows: 0 corresponds to low (<10%), and 1 to high 
expression (≥10%) at ×200 magnification. 
 
Figure 2. Kaplan-Meier estimates of period until the recurrence of seizure. 




cases with 1p/19q co-deletion and cases without the co-deletion (p = 0.016), and (b) cases 
with p53 upregulation and cases with normal p53 levels (p = 0.001). There was no 
significant difference in the mean periods controlled by a single anticonvulsant between 
(c) cases with tumors positive for ATRX staining and cases with tumors negative for 
ATRX (p = 0.181). 
